Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 585 of 5804
-
Could a pill replace chemo for some breast cancers?
Disease control Recruiting nowThis study is a multi-center, randomized, prospective phase II clinical trial aimed at exploring and evaluating the efficacy of dalpiciclib combined with AI in neoadjuvant treatment for ER strong positive(ER≥50%),HER2-negative, Ki-67≤20%,T1-3N1M0 postmenopausal breast cancer. The…
Phase: PHASE2 • Sponsor: Hebei Medical University Fourth Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Botox-Like shots could cut migraine days in half
Prevention OngoingThe purpose of this study is to understand the safety and effectiveness of the study drug, Dysport® when compared with placebo in preventing episodic migraine. A migraine is a headache with severe throbbing pain or a pulsating sensation, usually on one side of the head, and is o…
Phase: PHASE3 • Sponsor: Ipsen • Aim: Prevention
Last updated Jul 18, 2026 00:00 UTC
-
Could a Two-Drug combo outsmart resistant breast cancer?
Disease control Recruiting nowBreast cancer is not only the leading cause of cancer in women, but also the leading cause of cancer deaths in women. Estrogen receptor-positive and HER2-negative breast cancer is the most prevalent breast cancer subtype. Endocrine therapy is the mainstay of treatment; however, d…
Phase: PHASE2 • Sponsor: Northwestern University • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Stem cells offer new hope for stubborn eye ulcers
Disease control Recruiting nowThe proposed Conventional Cohort Expansion Study involves the use of Mesenchymal Stromal Cells (MSCs) are derived from the bone marrow. We previously studied the safety of subconjunctival injection of allogeneic bone marrow-derived MSCs in patients with nonhealing epitheliopathy …
Phase: PHASE2 • Sponsor: University of Illinois at Chicago • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Simple blood test could decide best therapy for advanced lung cancer
Disease control Recruiting nowThis clinical trial plans to assess to what extent the on-treatment circulating tumor DNA (ctDNA) can predict the subset of patients with NSCLC who will respond to immunotherapy treatment only and which patients will need both immunotherapy and chemotherapy modalities for their t…
Phase: PHASE2 • Sponsor: Hackensack Meridian Health • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New heart valve study aims to improve treatment for aortic stenosis
Disease control Recruiting nowEvaluation of the safety and performance of the Navitor TAVI System in a Global Study
Sponsor: Abbott Medical Devices • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New vaccine combo shows promise in ovarian cancer fight
Disease control Recruiting nowThis phase I/II trial tests the safety, side effects, best dose, and effectiveness of multi-epitope folate receptor alpha-loaded dendritic cell vaccine (FRalphaDC) with pembrolizumab in treating patients with ovarian, fallopian tube, or primary peritoneal cancer (collectively kno…
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New drug combo aims to slow advanced prostate cancer
Disease control CompletedThe purpose of this study is to determine whether the amount of time before disease progression can be prolonged in participants with metastatic castration-resistant prostate cancer (MCRPC) who receive lorigerlimab in addition to the standard of care (SOC) of docetaxel and predni…
Phase: PHASE2 • Sponsor: MacroGenics • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New combo drug CagriSema shows promise for diabetes and weight loss
Disease control CompletedThe study will look at how well CagriSema helps people lower their blood sugar and body weight. CagriSema is a new weekly medicine that combines two medicines called semaglutide and cagrilintide. CagriSema will be compared to the two medicines semaglutide and cagrilintide, when t…
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New drug cocktail aims to control aggressive lung cancer
Disease control Recruiting nowThis study has 2 cohorts: MOZART-ES cohort (for extensive-stage SCLC) and MOZART-LS cohort (for limited-stage SCLC). MOZART-ES cohort: Study treatment will consist of a platinum drug (carboplatin or cisplatin per investigator's choice) plus etoposide plus durvalumab plus monaliz…
Phase: PHASE2 • Sponsor: Hirva Mamdani • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Hope for lymphoma patients: new drug cocktail targets resistant cancer
Disease control Recruiting nowThis phase 2 trial studies the side effects and best dose of tazemetostat and zanubrutinib in combination with tafasitamab and lenalidomide, and to see how well these combinations work in treating patients with large B-cell lymphoma that returned or did not respond to earlier tre…
Phase: PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New drug duo aims to outsmart advanced kidney cancer
Disease control TerminatedThis study is a randomized, open label, multicenter Phase II trial to evaluate the efficacy and safety of botensilimab (a novel Fc enhanced Tree depleting anti-CTLA4) and balstilimab (a novel anti-PD1) relative to ipilimumab and nivolumab in treatment naïve patients with metastat…
Phase: PHASE2 • Sponsor: Michael B. Atkins, MD • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Freezing tumors may boost immunotherapy in stubborn melanoma
Disease control Recruiting nowThe aim of this study is to find out whether the combination of two approved drugs, ipilimumab and nivolumab, in combination with cryoablation are safe and effective for participants who have an unresectable melanoma that is resistant, or is growing, after receiving immunotherapy…
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Ancient herb takes on transplant complication: Withaferin-A tested for Steroid-Resistant GVHD
Disease control Recruiting nowStudy Design Prospective, single center, single arm, Phase II study. Research aims and objectives Aim: To evaluate the efficacy and safety of standardized Withaferin A in steroid refractory acute GvHD in patients post allogeneic stem cell transplantation Primary Objective: To…
Phase: PHASE2 • Sponsor: Tata Memorial Centre • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New hope for rare brain disorder: drug trial targets MSA
Disease control OngoingThis is a Phase 2, double-blind, parallel-group, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of multiple doses of ONO-2808 in patients with MSA. This is the first study of ONO-2808 in patients with MSA.
Phase: PHASE2 • Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New shot aims to cut dangerous COPD attacks in high-risk patients
Disease control CompletedThe purpose of this Phase III study is to evaluate the efficacy and safety of tozorakimab administered subcutaneously (SC) in adult participants with symptomatic COPD with a history of ≥ 2 moderate or ≥ 1 severe exacerbations of COPD in the 12 months prior to enrolment. Participa…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New drug XKH004 shows promise in phase 3 trial for back pain from ankylosing spondylitis
Disease control CompletedThis is a multicenter, randomized, double-blind, placebo-controlled, and parallel grouping study. Study procedures: The screening period does not exceed 4 weeks, including 16 weeks for initial treatment, 28 weeks for maintenance treatment and 8 weeks for safety follow-up.
Phase: PHASE3 • Sponsor: Zhejiang Kanova Biopharmaceutical Co., LTD • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Could a higher dose of tirzepatide tackle diabetes and obesity together?
Disease control OngoingThe main purpose of this study is to learn more about the safety and efficacy of investigational tirzepatide doses in participants with Type 2 diabetes and obesity that are already taking metformin. The study will last for about 89 weeks.
Phase: PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New pill targets rare bile duct cancer mutation in late-stage trial
Disease control OngoingThis study used a randomized, controlled, double-blind, multicenter Phase III clinical design with overall survival (OS) as the primary endpoint. About 165 patients with advanced biliary carcinoma were enrolled and randomly assigned to the experimental group and the control group…
Phase: PHASE3 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Electric field therapy plus radiation: new hope for pancreas cancer?
Disease control Recruiting nowThe purpose of this clinical trial is to determine whether using chemotherapy followed by stereotactic ablative body radiation therapy (SABR) and tumor treating fields (TTF) will slow tumor growth in people with locally advanced pancreas cancer. All participants will receive SABR…
Phase: NA • Sponsor: Baptist Health South Florida • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC